Table 2.
Association between MMP expression and clinical characteristics of PDAC. Red indicates that MMP levels are associated with poor outcome, blue indicates no association and green indicates that MMP levels are associated with improved survival.
| Member | Patient Number | Method | Correlation | Reference | |
|---|---|---|---|---|---|
| MMP1 | 45 PC, 10 CO | IHC | no | [36] | |
| MMP1 | 70 PC | IHC | no | [38] | |
| MMP1 | 46 PC, 5 CO | IHC | OS, | LM, Size, Stage | [30] |
| MMP1 | 30 PC | IHC | PNI | [33] | |
| MMP1 | 51 PC | IHC/serum | OS | [37] | |
| MMP2 | 75 PC, 10 CO | IHC | no | [36] | |
| MMP2 | 70 PC, 10 CO | IHC | no | [38] | |
| MMP2 | 51 PC | IHC/serum | no | [37] | |
| MMP2 | 32 PC, 31 CP | ELISA on tissue | no | [48] | |
| MMP2 | 37 PC, 7 CP | IHC | no | [50] | |
| MMP2 | 29 PC | IHC | no | [54] | |
| MMP2 | 127 PC, 25 CP, 25 CO | plasma | no | [55] | |
| MMP2 | 35 PC | RNA/IHC | no | [70] | |
| MMP2 | 32 PC | IHC | no | [120] | |
| MMP2 | 67 PC | IHC | LM, | PNI, OS, DF | [121] |
| MMP2 | 122 PC | IHC | OS, DF | [43] | |
| MMP2 | 127 PC | IHC | OS, Stage | [46] | |
| MMP2 | 20 PC | IHC | LM | [47] | |
| MMP2 | 37 PC, 7 CP | IHC | LM, DM | [50] | |
| MMP2 | 45 PC | IHC | OS, LM, Stage | [51] | |
| MMP2 | 30 PC, 17 CO | IHC | LM, Stage, Size | [53] | |
| MMP2 | 106 PC | RNA/WB | DM, Stage | [56] | |
| MMP2 | 40 PC, 10 CO | IHC | LM | [57] | |
| MMP2 | 67 PC, 20 CO | IHC | LM, Stage, PNI | [58] | |
| MMP2 | 33 PC, 14 CP, 13 CO | ZG/WB | Stage | [61] | |
| MMP2 | 92 PC, 43 CP, 91 CO | serum | LM, DM | [68] | |
| MMP2 | 32 PC | IHC | VI | [72] | |
| MMP2 | 88 PC | IHC | OS | [73] | |
| MMP3 | 45 PC, 10 CO | IHC | no | [36] | |
| MMP3 | 18 PC, 8 CO | RNA | no | [36] | |
| MMP3 | 70 PC | IHC | no | [38] | |
| MMP3 | 140 PC, 12 CO | IHC | OS | [95] | |
| MMP7 | 51 PC | IHC/serum | no | [37] | |
| MMP7 | 29 PC | IHC | no | [54] | |
| MMP7 | 88 PC | IHC | no | [73] | |
| MMP7 | 45 PC, 10 CO | IHC | OS, | LM, DIF, Stage | [36] |
| MMP7 | 70 PC | IHC | OS, | Size, DIF | [38] |
| MMP7 | 134 PC | IHC | Stage, PNI, | OS | [122] |
| MMP7 | 70 PC | RNA | LM, Size | [97] | |
| MMP7 | 47 PC, 10 CO | IHC | OS, DM | [99] | |
| MMP7 | 10 PC | RNA | OS | [104] | |
| MMP7 | 101 PC | serum | OS | [105] | |
| MMP7 | 39 PC | IHC | LM, OS | [123] | |
| MMP8 | 75 PC, 10 CO | IHC | no | [36] | |
| MMP8 | 91 PC, 41 CP, 30 CO | RNA (PBMCs) | no | [39] | |
| MMP9 | 45 PC, 10 CO | IHC | no | [36] | |
| MMP9 | 70 PC, 10 CO | IHC | no | [38] | |
| MMP9 | 51 PC | IHC/serum | no | [37] | |
| MMP9 | 91 PC, 41 CP, 30 CO | RNA (PBMCs) | no | [39] | |
| MMP9 | 29 PC | IHC | no | [54] | |
| MMP9 | 33 PC, 14 CP, 13 CO | ZG/WB | no | [61] | |
| MMP9 | 9 PC, 9 CO | MS/MS | no | [64] | |
| MMP9 | 35 PC | RNA/IHC | no | [70] | |
| MMP9 | 32 PC | IHC | no | [123] | |
| MMP9 | 27 PC | IHC | no | [124] | |
| MMP9 | 62 PC, 16 CO | IHC | PNI, | LM, Stage, Size | [66] |
| MMP9 | 63 PC | IHC | VI, | OS, LM, DM | [125] |
| MMP9 | 62 PC | IHC | LM, | OS | [126] |
| MMP9 | 32 PC, 31 CP | ELISA on tissue | LM | [48] | |
| MMP9 | 30 PC, 17 CO | IHC | LM, Stage, Size | [53] | |
| MMP9 | 36 PC | IHC | LM, DM | [63] | |
| MMP9 | 78 PC, 45 CP, 70 CO | serum | OS | [65] | |
| MMP9 | 103 PC, 6 CO | IHC | OS, LM, DM, VI, Stage | [67] | |
| MMP9 | 32 PC | IHC | VI | [72] | |
| MMP9 | 88 PC | IHC | OS, DF, | DM | [73] |
| MMP10 | 51 PC | IHC/serum | no | [37] | |
| MMP11 | 75 PC, 10 CO | IHC | OS, LM, | DIF, Size | [36] |
| MMP11 | not indicated | RNA | OS | [92] | |
| MMP12 | 75 PC, 10 CO | IHC | no | [36] | |
| MMP12 | 39 PC, 13 CO | RNA/WB/IHC | OS, | LM, Stage | [111] |
| MMP13 | 60 PC | IHC | LM | [41] | |
| MMP14 | 70 PC | IHC | no | [38] | |
| MMP14 | 75 PC, 10 CO | IHC | no | [36] | |
| MMP14 | 37 PC | RNA/IHC | no | [70] | |
| MMP15 | 78 PC | IHC | OS, DF, | PNI, LM, DM, Stage | [127] |
| MMP19 | 102 PC | IHC | OS, DF, PNI, Stage | [112] | |
| MMP20 | 102 PC | IHC | OS, DF, Stage, PNI | [112] | |
| MMP21 | 25 PC, 18 CO | IHC | no | [106] | |
| MMP26 | 25 PC, 18 CO | IHC | LM | [106] | |
| MMP28 | not indicated | RNA | OS | [113] | |
Pancreatic cancer (PC); pancreatitis (CP); healthy control (CO); benign tumor (BT); immunohistochemistry (IHC); Western blot (WB); zymography (DG); overall survival (OS); disease-free survival (DF); lymph node metastasis (LM); perineural invasion (PNI); venous invasion (VI); distant metastasis (DM); differentiation (DIF).